Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories

Front Oncol. 2023 Feb 8:13:1123029. doi: 10.3389/fonc.2023.1123029. eCollection 2023.

Abstract

The analysis of the immunogenetic background of multiple myeloma (MM) has proven key to understanding disease ontogeny. However, limited information is available regarding the immunoglobulin (IG) gene repertoire in MM cases carrying different heavy chain isotypes. Here, we studied the IG gene repertoire in a series of 523 MM patients, of whom 165 and 358 belonged to the IgA and IgG MM groups, respectively. IGHV3 subgroup genes predominated in both groups. However, at the individual gene level, significant (p<0.05) differences were identified regarding IGHV3-21 (frequent in IgG MM) and IGHV5-51 (frequent in IgA MM). Moreover, biased pairings were identified between certain IGHV genes and IGHD genes in IgA versus IgG MM. Turning to the imprints of somatic hypermutation (SHM), the bulk of rearrangements (IgA: 90.9%, IgG: 87.4%) were heavily mutated [exhibiting an IGHV germline identity (GI) <95%]. SHM topology analysis disclosed distinct patterns in IgA MM versus IgG MM cases expressing B cell receptor IG encoded by the same IGHV gene: the most pronounced examples concerned the IGHV3-23, IGHV3-30 and IGHV3-9 genes. Furthermore, differential SHM targeting was also identified between IgA MM versus IgG MM, particularly in cases utilizing certain IGHV genes, alluding to functional selection. Altogether, our detailed immunogenetic evaluation in the largest to-date series of IgA and IgG MM patients reveals certain distinct features in the IGH gene repertoires and SHM. These findings suggest distinct immune trajectories for IgA versus IgG MM, further underlining the role of external drive in the natural history of MM.

Keywords: immunogenetics; immunoglobulin a; immunoglobulin g; immunoglobulin gene repertoire; immunoglobulin isotypes; multiple myeloma; n-glycosylation; somatic hypermutation (SHM).

Grants and funding

This project was supported in part by the “Quant-ALL” project funded by Greece and the European Union with grant agreement no. MIS 5053938 and the project ODYSSEAS (Intelligent and Automated Systems for enabling the Design, Simulation, and Development of Integrated Processes and Products), implemented under the “Action for the Strategic Development on the Research and Technological Sector”, funded by the Operational Programme “Competitiveness, Entrepreneurship, and Innovation” (NSRF 2014-2020), and co-financed by Greece and the European Union with grant agreement no. MIS 5002462. This research was also co-financed by Greece and the European Union (European Regional Development Fund) through the Operational Programme “Competitiveness, Entrepreneurship, and Innovation” (NSRF 2014-2020) in the context of the project “BBMRI: Biobanking and Biomolecular Resources Research Infrastructure”, implemented under the action “Reinforcement of the Research and Innovation Infrastructure” (MIS5028275).